BTG.L on London Stock Exchange

30 Mar 2015
Change (% chg)

5.00p (+0.69%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BTG.L


BTG plc is a United Kingdom-based specialist healthcare company focused on developing and commercializing products targeting acute care, cancer and vascular diseases. The Company operates in three business segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. Its Interventional Medicines include Interventio... (more)


Beta: 0.39
Market Cap(Mil.): £2,744.98
Shares Outstanding(Mil.): 381.78
Dividend: --
Yield (%): --


  BTG.L Industry Sector
P/E (TTM): 66.11 40.31 40.78
EPS (TTM): 0.11 -- --
ROI: 6.13 16.86 16.19
ROE: 7.14 17.40 17.04
Search Stocks

BRIEF-Britihs pharma co BTG launches ADR programme

* Adr programme will be open for deposits from 9 a.m. (est) today Source text for Eikon: Further company coverage:

19 Feb 2015

British drugs company BTG lifts revenue guidance

LONDON, Feb 5 - British drugs company BTG lifted its forecast for annual revenues by as much as 4 percent on Thursday, citing the benefits of a U.S. acquisition and the reversal of currency headwinds.

05 Feb 2015

BRIEF-BTG raises full-year revenue forecast

* Full year revenue is now expected to be in range 345 mln-360 mln stg; previous guidance was 330 mln-345 mln stg

05 Feb 2015

BRIEF-BTG raises about 150 mln stg by placing new shares

* Placing raised proceeds of approximately 150 mln stg (before expenses)

04 Dec 2014

CORRECTED-BRIEF-BTG to acquire Pneumrx for up to $475 mln, funded by placing

* Announce that it has entered into an agreement to acquire pneumrx inc on a debt free cash free basis for an initial cash consideration of us$230 million

04 Dec 2014

BTG to buy lung intervention firm for up to $475 mln

LONDON, Dec 4 - BTG, the healthcare group best known for treating rattlesnake bites and varicose veins, is expanding into lung care by buying a Californian firm that has developed a device to prop open airways.

04 Dec 2014

BTG says long-awaited varicose vein treatment has positive debut

Nov 11 - British drugs company BTG said it had started to roll out its varicose vein treatment to a positive response in the United States, as it said revenue for the year would be at the top end of forecasts.

11 Nov 2014

BRIEF-BTG posts rise in H1 profit, sees full-year revenue at top end

* Operating profit increased to £42.8m (h1 13/14: £25.0m)

11 Nov 2014

BRIEF-BTG to supply DC Bead, Bead Block directly to doctors in Europe

* To supply DC Bead and Bead Block directly to physicians in Europe from 1 April 2015

13 Oct 2014

BRIEF-BTG settles Crofab patent litigation case against Bioclon, RDT

* BTG would allow Bioclon to begin selling crotalid antivenom relying on BTG's 414 patent from October 2018

10 Oct 2014

Earnings vs. Estimates

Search Stocks